Immunotherapy in patients with obesity — does weight change response?

Usually not. Most checkpoint inhibitor immunotherapy is now given as a fixed adult dose, the same for a 55 kg patient and a 105 kg patient, because body weight has only a modest effect on how much drug the body is exposed to. Where a per-kilogram dose is still used, it is calculated on actual weight, not a reduced one.

This surprises people, because almost every other medicine in a cancer plan is worked out from the body. Chemotherapy is calculated from body surface area. Steroids are calculated per kilogram. Immunotherapy, for the most part, is not. Several checkpoint inhibitors were first approved with a milligram-per-kilogram dose and later moved to one fixed dose for all adults, after pharmacokinetic modelling showed that the exposure achieved barely changed across the adult weight range. No medicine is named on this page — this describes the drug class, not a product.

The part worth holding on to is the second row of that table, because it is where an old fear lives. Doses are not quietly reduced because a patient is heavy. Guidance from ASCO on dosing systemic cancer treatment in adults with obesity says the opposite: capping or trimming a dose out of caution risks undertreating the cancer, and the full weight-based dose should be used unless there is a specific clinical reason not to. If a dose has been reduced for you, it is reasonable to ask which reason applied.

Dosing by weight remains standard in children, where body size varies far more across the age range — our page on immunotherapy in children and adolescents covers how that works and why paediatric use is a narrower and more specialised question.

On cost: where a fixed dose is used, the drug cost of a cycle does not rise with body weight. Where a per-kilogram dose is used, a heavier patient needs more drug per cycle and the cost can be higher. Any figure quoted to you is indicative, as of August 2026, and is confirmed in writing before treatment starts. At CION, immunotherapy is given as day care at our centres where it is genuinely indicated, and every plan is set by a tumour board rather than by a single doctor.

Possibly, and not in the direction most people expect. Retrospective studies of checkpoint inhibitor treatment have repeatedly reported that patients with a higher BMI did better on average than patients in the normal range. That is the obesity paradox. It is a consistent observation, it is not proven cause and effect, and it changes nobody's treatment plan.

This is the honest version of a finding that gets reported badly. It has turned up across melanoma, lung and kidney cancers, in more than one health system, which is why it is taken seriously rather than dismissed. One hypothesis under study is that the metabolic and hormonal signals produced by fat tissue alter how T cells behave, including how much PD-1 they carry. That work is laboratory science and early clinical observation, not established fact in patients. Four things should stop anyone leaning on it.

So what does it mean for you? Practically, one thing: a higher body weight is not a reason to expect immunotherapy to work less well, and nobody should be discouraged on that basis. It is equally not a reason to gain weight, to delay a decision, or to feel reassured about a treatment that may still not be the right one. No response figure is stated on this page, because a number of that kind belongs to a specific study population and not to an individual patient. Nothing here promises that any patient will be found eligible.

The reported picture is mixed. Some series find more immune-related side effects at a higher BMI, others find none, and all of it is observational. What is not in doubt is that obesity makes several early signs harder to read, because breathlessness, abnormal liver tests, high blood sugar and joint pain already have another explanation available.

That is the real risk here, and it is a recognition problem rather than a toxicity problem. Immune-related reactions are picked up early by noticing that something has changed. When every symptom already has a ready-made explanation, the change gets absorbed into the existing diagnosis and reported late. The table below is the one worth taking to a consultation.

Nothing in that table is a reason to withhold immunotherapy. It is the reason baseline blood tests matter more at a higher weight, not less, and the reason anything new or clearly worsening should be reported to your treating team the same day rather than waited out. One more link in the chain: the steroids used to control an immune reaction are dosed per kilogram, so a heavier patient receives a larger steroid dose, which pushes blood sugar up further and is another argument for having the diabetes properly controlled before cycle one.

No band rules anyone out. BMI is a starting point, not a gate. It matters here for two reasons only. The cut-offs used for Indian adults are lower than the international ones, so many patients are classified differently at home than abroad. And the highest bands change logistics rather than eligibility.

Two footnotes. BMI is height and weight only, so waist measurement adds information that BMI misses — the Indian consensus thresholds are 90 cm for men and 80 cm for women. And none of these bands appears anywhere in the eligibility criteria for immunotherapy. They shape the checks around the treatment, not the answer to whether you can have it.

Six things, and the weight is not the first of them. Whether the cancer qualifies at all. The baseline tests that obesity would otherwise blur. The doctors who already treat you. The practical arrangements. The tumour board decision. And a written list of what to report, for you and for whoever is at home.

1. 1

   Does the cancer qualify at all?

   Cancer type, stage and, where it applies, a biomarker test on the tumour. Most patients receive a no at this step, and body weight has nothing to do with it. This is the honest starting point: most patients in India are not candidates for immunotherapy.

2. 2

   Baseline tests, before anything starts

   Liver, kidney and thyroid function, fasting glucose and HbA1c, and a recorded weight. At a higher BMI these are what separate fatty liver from immune hepatitis, and existing diabetes from diabetes caused by the treatment, months later.

3. 3

   Bring in the doctors who already treat you

   The physician or endocrinologist managing the diabetes, the cardiologist, the respiratory or sleep team where apnoea is suspected, and a dietitian. A joint plan agreed before cycle one prevents a scramble at cycle three, and it is why this is a multidisciplinary assessment rather than one doctor's call.

4. 4

   Sort the practical things early

   Intravenous access, a correctly sized blood pressure cuff, a suitable infusion chair, and the table weight limit and bore diameter at the imaging centre where a response scan will be done. None of these changes eligibility. All of them are easier to solve a fortnight ahead than on the morning of a scan.

5. 5

   A tumour board decides, not one doctor

   Medical, surgical and radiation oncologists read the same file together, with the assessment attached. The board can also conclude that immunotherapy is not right for this patient, and says so plainly. An assessment cannot promise that a patient will be found eligible.

6. 6

   Everyone leaves with the warning list, in writing

   You and whoever is at home get the symptoms that need a same-day call. Where a memory difficulty or a mental health condition affects how symptoms get noticed and reported, that belongs in the plan too — see immunotherapy with dementia or cognitive impairment and immunotherapy and existing mental health conditions.

Treatment then runs as day care at a CION centre, with blood tests before each cycle, and any response-assessment PET-CT is coordinated at our partner imaging centres rather than performed in-house. Costs discussed with you are indicative, as of August 2026, and confirmed in writing before treatment starts.

Not deliberately, and not quickly. Cancer treatment is not the moment for a weight-loss programme. Weight lost during treatment is more often a warning sign than an achievement, and unintended weight loss is one of the findings a treating team takes most seriously. Holding weight and muscle steady is the realistic goal.

What is worth doing before starting is different, and more useful than a diet. Ask for a dietitian assessment rather than following a plan found online. Get the blood sugar into a controlled range, because that is the single change that most reduces trouble later if steroids are ever needed. Get sleep apnoea assessed if it has been suspected, because it is the commonest reason breathlessness is misread. Keep whatever activity is comfortable, since muscle is the part of body composition that actually predicts tolerance. Every one of those decisions belongs with your own treating team and dietitian, not with a page.

An eligibility explainer that only ever points one way is not much use either. Immunotherapy is not automatically the right treatment for a patient who happens to qualify, and choosing not to have it is a legitimate medical decision rather than a failure. These are the questions worth asking out loud at the consultation.

• Which criterion is the immunotherapy decision actually turning on — the cancer type, the stage, the biomarker result, or fitness?
• Was my weight given as a reason, and if so, what exactly did it change?
• Is the dose fixed or per kilogram, and if it is per kilogram, what does that mean for the cost of a cycle?
• Which baseline tests are being done before cycle one, and can I have a copy of the results?
• Who is managing my diabetes, my heart or my sleep apnoea while this runs, and have they been spoken to?
• What happens if we treat the symptoms well and do not give immunotherapy at all?

A team that answers all six honestly is giving you a framework rather than a recommendation, and that is what an eligibility conversation should be. Supportive and palliative care is active treatment rather than the absence of it, and it can run alongside a decision to treat just as easily as it can replace one.

Weight is one factor inside a larger eligibility question, and it is rarely the one that decides. These pages cover the situations families ask about next, where an existing condition or a stage of life changes the assessment rather than the answer.

• Immunotherapy in Children and Adolescents — where dosing genuinely is calculated by weight, and why paediatric use is a narrower, more specialised question than adult use.
• Immunotherapy in Patients With Dementia or Cognitive Impairment — what changes when the patient cannot reliably report a new symptom, and how the caregiver becomes part of the monitoring plan.
• Immunotherapy and Existing Mental Health Conditions — how an existing diagnosis is worked into the plan, and why it changes the support around treatment rather than eligibility.
• Immunotherapy at CION Cancer Clinics — how immunotherapy is delivered as day care, how response scans are coordinated with our partner imaging centres, and how costs are set out in writing.

If your weight has been given as the reason, that on its own is a reason to ask what was measured. Bring the reports, the medicine list and a recent height and weight, and you will leave with the three answers written down — dosing, response and side effects — including a no, if that is what the assessment supports.

This page is general information and does not replace a consultation. It describes a treatment class only, names no medicine or brand, recommends no treatment, and does not promise that any patient will be found eligible. BMI categories are drawn from WHO definitions and from the Indian consensus thresholds endorsed by ICMR; dosing guidance for adults with obesity is drawn from ASCO; eligibility for immunotherapy follows NCCN, ASCO and ESMO patient-education guidance current in August 2026, which is revised over time. The obesity paradox is described here as a reported observation from retrospective studies, not as an established effect. No survival figure or response percentage is stated or implied anywhere on this page. Every decision about assessment, treatment, diet and the alternatives belongs with your own treating team.

A written second opinion on eligibility

Free, 45 minutes, reviewed by a tumour board — including the honest answer when immunotherapy is not the right treatment.